Evidence map›Paper›PMID 25350297›Full record

ArticleTranslational psychiatry2014

Investigation of blood mRNA biomarkers for suicidality in an independent sample.

N Mullins, K Hodgson, K E Tansey, N Perroud, W Maier, O Mors, M Rietschel, J Hauser, N Henigsberg, D Souery and 6 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. The Impact ofInternational journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 8 countries.

N MullinsMRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK.
K HodgsonMRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK.
K E TanseyMRC Centre for Neuropsychiatric Genetics and Genomics, Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK.
N PerroudDepartment of Mental Health and Psychiatry, University Hospital of Geneva, Geneva, Switzerland.
W MaierDepartment of Psychiatry, University of Bonn, Bonn, Germany.
O MorsResearch Department P, Aarhus University Hospital, Risskov, Denmark.
M Rietschel1] Department of Psychiatry, University of Bonn, Bonn, Germany [2] Division of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, Germany.
J HauserLaboratory of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland.
N HenigsbergCroatian Institute for Brain Research, University of Zagreb, Zagreb, Croatia.ORCID 0000000253031834
D Souery1] Laboratoire de Psychologie Médicale, Université Libre de Bruxelles, Brussels, Belgium [2] PsyPluriel - Centre Européen de Psychologie Médicale, Brussels, Belgium.
K Aitchison1] MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK [2] Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.ORCID 0000000211073024
A FarmerMRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK.
P McGuffinMRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK.
G Breen1] MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK [2] NIHR Biomedical Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King's College London, London, UK.ORCID 0000000320531792
R Uher1] MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK [2] Department of Psychiatry, Dalhousie University, 5909 Veterans' Memorial Lane, Halifax, NS, Canada.
C M Lewis1] MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK [2] Division of Genetics and Molecular Medicine, King's College London School of Medicine, Guy's Hospital, London, UK.
King's College London · GBUniversity of Bonn · DEAarhus University Hospital · DKCardiff University · GBGuy's Hospital · GBPoznan University of Medical Sciences · PLUniversité Libre de Bruxelles · BEUniversity Hospital of Geneva · CHUniversity of Alberta · CAUniversity of King's College · CAUniversity of Zagreb · HR

Funding

Medical Research Council G0701420
6 · The paper itself

Abstract

Changes in the blood expression levels of SAT1, PTEN, MAP3K3 and MARCKS genes have been reported as biomarkers of high versus low suicidality state (Le-Niculescu et al.). Here, we investigate these expression biomarkers in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, of patients with major depressive disorder on a 12-week antidepressant treatment. Blood gene expression levels were available at baseline and week 8 for patients who experienced suicidal ideation during the study (n=20) versus those who did not (n=37). The analysis is well powered to detect the effect sizes reported in the original paper. Within either group, there was no significant change in the expression of these four genes over the course of the study, despite increasing suicidal ideation or initiation of antidepressant treatment. Comparison of the groups showed that the gene expression did not differ between patients with or without treatment-related suicidality. This independent study does not support the validity of the proposed biomarkers.

Indexed as

Suicidal IdeationAcetyltransferasesAdultAntidepressive AgentsDiamine N-AcetyltransferaseFemaleFollow-Up StudiesGene ExpressionGenetic MarkersHumansIntracellular Signaling Peptides and ProteinsMajor Depressive DisorderMaleMAP Kinase Kinase Kinase 3Membrane ProteinsMiddle AgedAcetyltransferasesAntidepressive AgentsDiamine N-AcetyltransferaseGenetic MarkersIntracellular Signaling Peptides and ProteinsMAP3K3 protein, humanMAP Kinase Kinase Kinase 3MARCKS protein, humanMembrane ProteinsMyristoylated Alanine-Rich C Kinase SubstratePTEN PhosphohydrolasePTEN protein, humanRNA, Messenger

Identifiers

PMID25350297
PMCPMC4350518
OpenAlexW2061381094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.